Skip to Content

EAN24: Efgartigimod in Generalized Myasthenia Gravis are Well Tolerated and Efficacious

The ADAPT study has provided interesting evidence supporting the use of efgartigimod in treating generalized myasthenia gravis. Efgartigimod, an FcRn antagonist, selectively reduces pathogenic IgG antibodies, resulting in clinically meaningful improvements in both function and muscle strength.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top